CFP and neoplasm: The results of these experiments showed that, compared with other CTX doses (50 mg kg−1 and 100 mg kg−1) usually used in tumor immunotherapy, only the dose of 150 mg kg−1 CTX controlled the CFP-B16 tumor growth successfully when CTX was used alone as well as when it was used in combination with ACT (Figure 2—figure supplement 1A).